On December 16th, Shanghai Stock Exchange China Securities Network (Reporter Wang Mopujia) announced that Maiwei Biotechnology has signed a "Maiwei Biotechnology Bone Health Innovation Drug Project Contract" with the Chongqing High tech Industrial Development Zone Management Committee (referred to as "Chongqing High tech Zone Management Committee") and the Chongqing Zhongxin Pharmaceutical Big Health Private Equity Investment Fund Partnership Enterprise (Limited Partnership) (referred to as "Big Health Fund"). Maiwei Biotechnology (Chongqing) Co., Ltd. (referred to as "Maiwei Chongqing"), a wholly-owned subsidiary of the company, will jointly invest in and construct the "Maiwei Biotechnology Bone Health Innovation Drug Project" as the project operating entity.

It is reported that the total planned investment for the above-mentioned project is 2 billion yuan, of which Maiwei Biotechnology has a total investment of no less than 1.6 billion yuan (1.008 billion yuan in this round of investment), which will be contributed in the form of intangible assets; The Big Health Fund plans to invest a total of 400 million yuan (200 million yuan in this round of investment) in monetary form.

According to the project contract, the Chongqing High tech Zone Management Committee will support the account opening work of Maiwei Biotechnology's biopharmaceuticals in medical institutions in Chongqing, and support Mailishu ® Promote new service methods such as the "Benefit the People Project" and "Chongqing Kuaibao" value-added services throughout the city, aiming to cover over 1 million elderly people annually.

Maiwei Chongqing will receive Mailishu ® The rights and interests of research, production, sales, commercialization, and market promotion include the domestic market (mainland China, Hong Kong, Macao, and Taiwan) and all international markets. Maiwei Chongqing will also build Mailishu ® The National Marketing Center is conducting a marketing campaign for Malishu ® Clinical registration studies and post market clinical trials (including real-world studies) aimed at expanding indications for drugs that have already been marketed.

It is understood that Malishu ® It is the second Prolia approved for market worldwide ® (Proli) ®） Biosimilars were approved in March 2023 for osteoporosis in postmenopausal women at high risk of fractures. In postmenopausal women, this product can significantly reduce the risk of vertebral, non vertebral, and hip fractures. Desumab is a first-line broad-spectrum anti fracture risk drug internationally, which can significantly reduce the risk of fractures in multiple locations of patients, including vertebral, non vertebral, and hip fractures. Disumab has been included in the national Class B medical insurance catalog.

Maiwei Biotechnology stated that the above-mentioned project focuses on developing denosumab for the treatment of osteoporosis, leveraging the ecosystem through fund investment and industrial innovation, exploring a new governance model for the elderly society of "health management+scientific prevention and treatment+multi-party co treatment", and combining bone health screening and prevention with public health projects for the elderly.